Learnings about the complexity of extracellular tau aid development of a blood‐based screen for Alzheimer's disease

Abstract

The forms of tau in CSF and plasma are distinct, but in each specimen type, the levels of certain fragments are increased in AD. Measurement of plasma NT1 tau should be aggressively pursued as a potential blood-based screening test for AD/AD-MCI.